- NCIt
- C3512
- OncoTree
- LUAD
- DOID
- 3910
- UMLS CUI
- C0152013
- MeSH
- D000077192
Loading cancer entity…
Loading cancer entity…
Clinical trials
231 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (28)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03361319 | Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma(N3) | withdrawn | Phase 1 / Phase 2 | 0 | Royal Marsden NHS Foundation TrustOTHER | 0 | Nov 24, 2020 | clinicaltrials |
| NCT01958372 | Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer | completed | Phase 1 | 11 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Nov 23, 2020 |
| clinicaltrials |
| NCT02616211 | An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors | completed | — | 15 | Mayo ClinicOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04554875 | Derivation and Validation of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules | unknown | — | 1,000 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Sep 18, 2020 | clinicaltrials |
| NCT00950365 | Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 79 | Albert Einstein College of MedicineOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT01218516 | A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung | completed | Phase 2 | 130 | MorphotekINDUSTRY | 8 | Aug 20, 2020 | clinicaltrials |
| NCT04493827 | Distribution and Prognostic Impact of Oncogenic Drivers in Metastatic Lung Adenocarcinoma : a Retrospective Monocentric Study in Nancy University Hospital Center | completed | — | 114 | Central Hospital, Nancy, FranceOTHER | 1 | Jul 30, 2020 | clinicaltrials |
| NCT04482829 | TCM in the Treatment of Lung Adenocarcinoma | unknown | N/A | 144 | Henan University of Traditional Chinese MedicineOTHER | 0 | Jul 23, 2020 | clinicaltrials |
| NCT02737774 | Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation | unknown | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 1, 2020 | clinicaltrials |
| NCT04086680 | The Detection of EGFR Mutations in Liquid Based Cytology Samples | completed | — | 13 | Royal Cornwall Hospitals TrustOTHER | 1 | Jun 22, 2020 | clinicaltrials |
| NCT00073398 | Vaccine Treatment for Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 54 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT03704870 | Outcomes Following Omission of Daily Routine Chest Radiographs Following Pulmonary Resection | completed | Phase 2 | 50 | University Health Network, TorontoOTHER | 1 | May 1, 2020 | clinicaltrials |
| NCT02134912 | S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib | terminated | Phase 2 | 1 | SWOG Cancer Research NetworkNETWORK | 1 | Feb 20, 2020 | clinicaltrials |
| NCT03059641 | Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China | completed | — | 300 | Geneplus-Beijing Co. Ltd.INDUSTRY | 1 | Feb 5, 2020 | clinicaltrials |
| NCT01707823 | Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer | terminated | Early Phase 1 | 4 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT03544814 | EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression | completed | Phase 2 | 99 | Shanghai Chest HospitalOTHER | 0 | Oct 15, 2019 | clinicaltrials |
| NCT01259089 | Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 38 | Northwestern UniversityOTHER | 1 | Sep 11, 2019 | clinicaltrials |
| NCT02466568 | Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung | withdrawn | Phase 1 / Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Sep 9, 2019 | clinicaltrials |
| NCT00126581 | Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer | completed | Phase 2 | 188 | National Cancer Institute (NCI)NIH | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01362790 | SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2019 | clinicaltrials |
| NCT03905317 | Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene | unknown | Phase 2 | 66 | Sun Yat-sen UniversityOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT03838588 | The Tracking Molecular Evolution for NSCLC (T-MENC) Study | unknown | — | 200 | Geneplus-Beijing Co. Ltd.INDUSTRY | 1 | Feb 12, 2019 | clinicaltrials |
| NCT02891733 | Retrospective Analysis of the Expression of the Neurotensin Receptor by Metastatic Lung Adenocarcinomas(NTS) | withdrawn | — | 0 | Fondation Hôpital Saint-JosephOTHER | 0 | Feb 4, 2019 | clinicaltrials |
| NCT01578551 | Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. | terminated | Phase 2 | 25 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT01557959 | Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 45 | Wake Forest University Health SciencesOTHER | 1 | Jun 29, 2018 | clinicaltrials |
| NCT00955305 | Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | terminated | Phase 2 | 175 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2018 | clinicaltrials |
| NCT02979821 | Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001) | completed | Phase 2 | 6 | Korean Association for the Study of Targeted TherapyOTHER | 1 | May 24, 2018 | clinicaltrials |
| NCT03486496 | Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation(Geber) | unknown | Phase 2 | 50 | Fujian Cancer HospitalOTHER_GOV | 1 | Apr 3, 2018 | clinicaltrials |
| NCT02093000 | A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma | completed | — | 201 | Hoffmann-La RocheINDUSTRY | 1 | Feb 23, 2018 | clinicaltrials |
| NCT03351842 | Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20% | recruiting | Phase 2 | 460 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 19, 2017 | clinicaltrials |
| NCT03376737 | Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma | unknown | Phase 2 | 120 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 18, 2017 | clinicaltrials |
| NCT02121925 | Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up(ONC003) | terminated | — | 227 | Myriad Genetic Laboratories, Inc.INDUSTRY | 1 | Sep 5, 2017 | clinicaltrials |
| NCT02715102 | Circulating Tumor DNA in Patients at High Risk for Lung Cancer | terminated | — | 39 | Pathway GenomicsINDUSTRY | 1 | Aug 21, 2017 | clinicaltrials |
| NCT02679443 | Vitamin Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy(PEMVITASTART) | completed | N/A | 161 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT01726296 | Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care | completed | N/A | 1,440 | Fox Chase Cancer CenterOTHER | 1 | Apr 6, 2017 | clinicaltrials |
| NCT03090815 | Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma | unknown | — | 100 | The University of Hong KongOTHER | 1 | Mar 27, 2017 | clinicaltrials |
| NCT02282267 | Blood Detection of EGFR Mutation For Iressa Treatment(Benefit) | unknown | N/A | 188 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 24, 2017 | clinicaltrials |
| NCT01294306 | MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2016 | clinicaltrials |
| NCT02787447 | Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy | unknown | Phase 2 | 46 | First People's Hospital of HangzhouOTHER | 1 | Nov 25, 2016 | clinicaltrials |
| NCT02951897 | Application of Detecting Circulating Tumor Cells in the Accurate Treatment of Early Stage Lung Adenocarcinoma(CTCs detection) | unknown | N/A | 120 | Third Military Medical UniversityOTHER | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02951637 | Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial | unknown | Phase 2 | 300 | Shanghai Chest HospitalOTHER | 0 | Nov 1, 2016 | clinicaltrials |
| NCT02946216 | ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC | unknown | — | 200 | First People's Hospital of HangzhouOTHER | 1 | Oct 27, 2016 | clinicaltrials |
| NCT02898857 | Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma(NOTCH) | unknown | — | 18 | University Hospital, MontpellierOTHER | 1 | Sep 13, 2016 | clinicaltrials |
| NCT02843711 | Molecular Analysis of 150 Lung Adenocarcinoma(LUNG-EST) | unknown | — | 152 | Hospices Civils de LyonOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT02804646 | Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma | unknown | Phase 4 | 100 | Anhui Provincial HospitalOTHER_GOV | 1 | Jun 21, 2016 | clinicaltrials |
| NCT02788058 | A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy | unknown | Phase 2 | 76 | First People's Hospital of HangzhouOTHER | 0 | Jun 2, 2016 | clinicaltrials |
| NCT02738684 | A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test | unknown | — | 100 | Southwest Hospital, ChinaOTHER | 0 | Apr 14, 2016 | clinicaltrials |
| NCT01819428 | NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma | terminated | Phase 2 | 22 | National OncoVentureOTHER | 1 | Mar 1, 2016 | clinicaltrials |
| NCT02691871 | Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR | unknown | Phase 1 | 20 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Feb 25, 2016 | clinicaltrials |
| NCT02493582 | The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR | active not recruiting | Phase 2 | 400 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 5, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Nov 24, 2020source: clinicaltrials